N (%) | Median (Range) | |
Follow-Up of the Surviving Patients (months) |
| 30.4 (2.5 - 81.2) |
Follow-Up for All Patients (months) |
| 18 (1.2 - 81.2) |
Age (years) | 70.5 (41.7 - 91.1) | |
Prescription Dose (Gy) |
| 62 (43.1 - 74.0) 1.8 |
Mean Lung Dose (Gy) | 13.6 (4.4 - 22.4) | |
Lung V20 (%) | 23.9 (5.7 - 41.5) | |
Tumor Volume [cc] (CTV) |
| 118.5 (1.1 - 706) |
Technique 3D-CRT | 49 (41.2%) |
|
IMRT | 70 (58.8%) |
|
Stage IIIA | 72 (60.5%) | |
IIIB | 47 (39.5%) | |
Chemo Yes | 106 (89.1%) | |
No | 13 (10.9%) | |
Laterality Left | 44 (37%) | |
Right | 74 (62.2%) | |
Undefined | 1 (0.8%) | |
Site Lower Lobe | 26 (21.8%) | |
Middle Lobe | 5 (4.2%) | |
Upper Lobe | 80 (67.2%) | |
Bronchus | 5 (4.2%) | |
Undefined | 3 (2.5%) | |
Alive at Last Follow-up | 47 (39.5%) | |
Deceased at Last Follow-Up | 72 (60.5%) |